Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to 546.15%.

  • Arcus Biosciences' EBIT Margin fell 3274000.0% to 546.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.25%, marking a year-over-year decrease of 353400.0%. This contributed to the annual value of 127.91% for FY2024, which is 1626900.0% up from last year.
  • Per Arcus Biosciences' latest filing, its EBIT Margin stood at 546.15% for Q3 2025, which was down 3274000.0% from 5.0% recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' EBIT Margin registered a high of 79.25% during Q4 2021, and its lowest value of 825.87% during Q3 2021.
  • For the 5-year period, Arcus Biosciences' EBIT Margin averaged around 338.75%, with its median value being 286.21% (2023).
  • The largest annual percentage gain for Arcus Biosciences' EBIT Margin in the last 5 years was 17881200bps (2021), contrasted with its biggest fall of -8282800bps (2021).
  • Arcus Biosciences' EBIT Margin (Quarter) stood at 79.25% in 2021, then plummeted by -375bps to 217.65% in 2022, then plummeted by -35bps to 293.55% in 2023, then crashed by -35bps to 396.15% in 2024, then tumbled by -38bps to 546.15% in 2025.
  • Its last three reported values are 546.15% in Q3 2025, 5.0% for Q2 2025, and 435.71% during Q1 2025.